Physician profile
James R Buckner
NPI 1407030349
$420.63
in general payments reported to CMS, 2019-2025
13 companies · $210 in 2025
The $210 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $140 · 2020: $48.80 · 2024: $22.16 · 2025: $210.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $232.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $231.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $63.39 | 2019-2025 | Breztri, Airsupra |
| Allergan, INC. | $48.98 | 2019-2020 | |
| Novo Nordisk INC | $47.27 | 2025 | Ozempic, Rybelsus |
| Viatris Specialty LLC | $41.19 | 2025 | Yupelri |
| Exact Sciences Corporation | $37.07 | 2024-2025 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $34.80 | 2025 | Caplyta |
| Mylan Specialty L.P. | $33.94 | 2019 | |
| Pfizer INC. | $30.72 | 2019 | |
| Astellas Pharma US INC | $21.30 | 2025 | Veozah |
| Vertex Pharmaceuticals Incorporated | $20.02 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.35 | 2019 | |
| Glaxosmithkline, LLC. | $13.44 | 2019 | |
| Lilly USA, LLC | $11.16 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Buckner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.